

## Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

ROCÍO GARCÍA-CARBONERO, ERIC VAN CUTSEM, FERNANDO RIVERA, JACEK JASSEM, IRA GORE JR, NIAL TEBBUTT, FADI BRAITEH, GUILLEM ARGILES, ZEV A. WAINBERG, ROEL FUNKE, MARIA ANDERSON, BRUCE MCCALL, MARK STROH, ERIC WAKSHULL, PRITI HEGDE, WEILAN YE, DANIEL CHEN, ILSUNG CHANG, INA RHEE, HERBERT HURWITZ

*The Oncologist* 2017;22:375–376; first published on March 8, 2017; <http://dx.doi.org/10.1634/theoncologist.2016-0133>

In the Clinical Trial Results “Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer”, published in the April 2017 issue of *The Oncologist*, the affiliation for Dr. Jacek Jassem was incorrect. The correct affiliation is Medical University of Gdansk, Gdansk, Poland. This error has been corrected in the online version of the article.